Some features of intraoperative infusion-transfusion therapy when performing cytoreductive operations with the use of hyperthermic intraperitoneal chemotherapy in patients with ovarian cancer: retrospective cohort study
#2021-3
PDF_2021-3_126-132 (Русский)
HTML_2021-3_126-132 (Русский)

Keywords

ovarian cancer
anesthesia
cytoreductive surgery
hyperthermic intraperitoneal chemotherapy (HIPEC)
infusion-transfusion therapy

How to Cite

Morikov D.D., Shelekhov A.V., Gorbachev V.I., Dvornichenko V.V., Pavlov A.G., Radostev S.I. Some features of intraoperative infusion-transfusion therapy when performing cytoreductive operations with the use of hyperthermic intraperitoneal chemotherapy in patients with ovarian cancer: retrospective cohort study. Annals of Critical Care. 2021;(3):126–132. doi:10.21320/1818-474X-2021-3-126-132.

Statistic

Abstract Views: 39
PDF_2021-3_126-132 (Русский) Downloads: 7
HTML_2021-3_126-132 (Русский) Downloads: 7
Statistic from 21.01.2023

Abstract

Introduction. Сytoreductive operations with using hyperthermic intraoperative intraperitoneal chemotherapy(CR + HIPEC) is an effective technology in the treatment of locally advanced and metastatic ovarian cancer, the relevance of the treatment of this one’s is beyond doubt. The neсessity of protection organs and systems of the body from a stress response, correction of water and electrolyte balance, blood loss, volemia, and prevention of the toxic effects of chemotherapy make infusion-transfusion therapy (ITT) one of the main components of anesthesia during such operations. Objectives. An analyze the qualitative and quantitative composition of perioperative infusion-transfusion therapy in patients with advanced stages of ovarian cancer during cytoreductive operation with the addition of HIPEC of the abdominal cavity. Materials and methods. In retrospective study 84 patients, 2 types of surgical interventions and anesthetic accompaniment were analyzed, depending on the availability of HIPEC. The duration of the anesthetic treatment, the doses of the anesthetics, the volume of blood loss, the volume and quality of intraoperative infusion therapy were assessed. Results. With ITT carried out with cytoreduction using GIIH, the volume of administration of crystalloid solutions increases by 2.3 times; the average value of the infusion volume increases by 16 (10,5–20) ml/kg/hour. When analyzing the proportional ratio of crystalloid and colloidal solutions, their qualitative composition with CR + GIIH consists of: erythrocyte suspension 3.1 %, FFP 13.6 %, colloidal solutions 8.52 %, crystalloid solutions 74.6 % of total infusion’s volume. Conclusions. Perioperative ITT performed with cytoreduction using GIIH differs significantly from ITT without that. The necessity for high-volume infusion-transfusion therapy by increasing the introduction of crystalloids during cytoreductive operations with hyperthermic intraoperative intraperitoneal chemotherapy was revealed. This technique had no complications and allowed maintaining the stability of hemodynamics, volumetric volume and the required volume of diuresis. The use of a “balanced electrolyte solution” is preferable for intraoperative high-volume ITT.

https://doi.org/10.21320/1818-474X-2021-3-126-132
PDF_2021-3_126-132 (Русский)
HTML_2021-3_126-132 (Русский)

References

  1. Киреева Г.С., Сенчик К.Ю., Гафтон Г.И. и др. Химиоперфузионное лечение злокачественных опухолей. Санкт-Петербург: СпецЛит, 2018. [Kireeva G.S., Senchik K.Yu., GaftonG I., et al. Chemoperfusion treatment of malignanttumors. St. Petersburg: SpetsLit, 2018. (In Russ)]
  2. Cortez A.J., Tudrej P., Kujawa K.A., et al. Advances in ovarian cancer therapy. Cancer Chemother Pharmacol. 2018; 81: 17–38. DOI: 10.1007/s00280-017-3501-8
  3. Charo L.M., Jou J., Binder P., et al. Current status of hyperthermic intraperitoneal chemotherapy (HIPEG) for ovarian cancer in the United States. Gynecol Oncol. 2020; 159(3): 681–6. DOI: 10.1016/j.ygyno.2020.09.022
  4. Хороненко В.Э., Шеметова М.М., Дрожжина О.В. идр. Анестезиологическое обеспечение и интенсивная терапия при проведении гипертермической интраоперационной внутрибрюшной химиотерапии у больных раком желудка. Обзор литературы и собственный клинический опыт. Анестезиология и реаниматология. 2015; 60(1): 50–4. [Khoronenko V.E., Shemetova M.M., Drozhzhina O.V., et al. Anaesthesia and intensive care during intraoperative intraperitonealhyperthermic chemotherapy in patients with gastric cancer (literature review and own clinical experience). Anesteziologiya i reanimatologiya. 2015; 60(1): 50–4. (In Russ)]
  5. Шелехов А.В., ДворниченкоВ.В., Радостев С.И. и др. Опыт применения технологии циторедуктивной хирургии с методом интраоперационной интраперитонеальной гипертермической химиотерапии в лечении больных распространенным раком яичников. Сибирский онкологический журнал. 2018; 17(3): 58–63. DOI: 10.21294/1814-4861-2018-17-3-58-63 [Shelekhov A.V., Dvornichenko V.V., Radostev S.I., et al. Experience in applying the technology of cytoreductive surgery with hyperthermic intraoperative intraperitoneal chemotherapy in the treatment of patients with peritoneal carcinomatosis. Siberian journal of oncology. 2018; 17(3): 58–63. DOI: 10.21294/1814-4861-2018-17-3-58-63 (In Russ)]
  6. Мориков Д.Д., ШелеховА.В., Горбачев В.И. и др. Анестезиологическое обеспечение циторедуктивных операций с применением гипертермической внутрибрюшинной химиотерапии у больных раком яичника. Вестник анестезиологии и реаниматологии. 2019; 16(5): 24–30. DOI: 10.21292/2078-5658-2019-16-5-24-30 [Morikov D.D., Shelekhov A.V., Gorbachev V.I., et al. Anesthesiological support of cytoreducative operations using hyperthermic intraperitoneal chemotherapy (HIPEC) in patients with ovaryan cancer. Messenger of anesthesiologyandresuscitation. 2019; 16(5): 24–30. DOI: 10.21292/2078-5658-2019-16-5-24-30 (In Russ)]
  7. Raspe C., Fletcher L., Schneider R., et al. Best practice for perioperative management of patients with cytoreductive surgery and HIPEG. European journal of surgical oncology. 2017; 43(6): 1013–27. DOI: 10.1016/j.ejso.2016.19.008
  8. Dellinger T.H., Han E.S. State of the Science: The role of HIPEC in the treatment of ovarian cancer. Gynecol Oncol. 2021;160(2): 364–8. DOI: 10.1016/j.ygyno.2020.12.029
Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.

Copyright (c) 2021 ANNALS OF CRITICAL CARE